Published in Cell Death Differ on November 01, 2002
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol (2007) 1.15
Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar Drugs (2010) 1.08
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol (2009) 1.01
Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents (2004) 0.94
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides. PLoS One (2014) 0.86
Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer (2010) 0.85
Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs (2007) 0.80
Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Eur J Med Chem (2015) 0.79
P-glycoprotein is not involved in pathway of anti-Fas/Fas-induced apoptosis in KBv200 cells. World J Gastroenterol (2005) 0.78
ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. J Cancer Res Clin Oncol (2012) 0.78
Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Exp Cell Res (2015) 0.76
Mechanisms of apoptosis are retained in cells with P glycoprotein-mediated drug resistance. Dokl Biol Sci (2006) 0.75
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
A functional neo-centromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA. Nat Genet (1997) 3.36
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene (1997) 2.35
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
The 10q25 neocentromere and its inactive progenitor have identical primary nucleotide sequence: further evidence for epigenetic modification. Genome Res (2000) 1.96
Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med (2000) 1.89
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A (1998) 1.60
Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 1.58
Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci U S A (1992) 1.55
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene (2011) 1.52
Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med (1999) 1.45
CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol (2007) 1.45
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Prophylactic Use of Sulphonamide in Obstetrics. Br Med J (1938) 1.42
Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol (2001) 1.40
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem (1998) 1.36
Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3. J Biol Chem (2000) 1.32
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med (1990) 1.24
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 1.19
Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. Transpl Immunol (1993) 1.19
Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem (1996) 1.17
Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody. Biochem Biophys Res Commun (1993) 1.14
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene (2013) 1.11
p53-dependent ceramide response to genotoxic stress. J Clin Invest (1998) 1.11
Direct cloning of human 10q25 neocentromere DNA using transformation-associated recombination (TAR) in yeast. Genomics (1998) 1.10
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol (2001) 1.07
Exploration of the Common Bile Duct for Stone. Drainage with T-Tube and Cholangiography. Br Med J (1941) 1.07
CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today (1999) 1.07
Evolution in action. Nature (1974) 1.06
Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids. Oncogene (2006) 1.05
NK cells and apoptosis. Immunol Cell Biol (1999) 1.04
Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol (2000) 1.02
Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens (2009) 1.01
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 1.00
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood (2000) 1.00
Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res (1999) 0.99
A role for P-glycoprotein in regulating cell death. Leuk Lymphoma (2000) 0.99
Role of TNF in lymphocyte-mediated cytotoxicity. Microsc Res Tech (2000) 0.98
Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ (2004) 0.96
Granule serine proteases are normal nuclear constituents of natural killer cells. J Biol Chem (1994) 0.95
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol (2000) 0.94
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis (2012) 0.94
Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. Biochem J (2001) 0.93
Automated single-cell manipulation and sorting by light trapping. Appl Opt (1987) 0.93
Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. Cell Death Differ (2008) 0.93
Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis. J Biol Chem (2000) 0.92
Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ (1998) 0.92
Bcl-2 acts upstream of the PARP protease and prevents its activation. Cell Death Differ (1997) 0.92
Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol (1992) 0.92
A British Medical Association Lecture on DIFFICULT LABOUR. Br Med J (1929) 0.91
The restricted expression of granzyme M in human lymphocytes. J Immunol (2001) 0.91
Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. Cell Death Differ (2000) 0.90
The subunit structure of the aliphatic amidase from Pseudomonas aeruginosa. Eur J Biochem (1973) 0.90
Mechanisms of interferon mediated anti-viral resistance. Curr Drug Targets Immune Endocr Metabol Disord (2001) 0.90
Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther (2010) 0.89
Functional characterisation of alternatively spliced CD46 cytoplasmic tails. Transplant Proc (1992) 0.89
Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol (2001) 0.88
Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol (1998) 0.88
Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med (2000) 0.87
Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res (1998) 0.87
The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics (1994) 0.86
Strong associations between RFLP and protein polymorphisms for CD46. Immunogenetics (1992) 0.85
Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. J Neuroimmunol (1992) 0.85
m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med (1999) 0.85
Adoptive transfer: the role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. Xenotransplantation (1998) 0.85
Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. J Immunol (1999) 0.84
Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets (2002) 0.84
Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther (2007) 0.83
The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. J Leukoc Biol (1998) 0.83
Killing by cytotoxic T cells and natural killer cells: multiple granule serine proteases as initiators of DNA fragmentation. Immunol Cell Biol (1993) 0.83
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis (2013) 0.83
Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. Transplant Proc (1994) 0.83
Rapid cloning of mouse DNA as yeast artificial chromosomes by transformation-associated recombination (TAR). Mamm Genome (1998) 0.83